Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;145(2):173-9.
doi: 10.1111/j.1365-2141.2009.07606.x. Epub 2009 Feb 19.

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

Liuyan Jiang  1 , Constance M Yuan, Julia Hubacheck, John E Janik, Wyndham Wilson, John C Morris, Gregory A Jasper, Maryalice Stetler-Stevenson
Affiliations

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

Liuyan Jiang et al. Br J Haematol. 2009 Apr.

Abstract

The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92.3%), ATLL (94.1%) and CTCL (87.5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CD52 Expression in T Cell Malignancies. CD52 expression as measured by anti-CD52-PE antibody. A. High level CD52 expression (ABC-24,894). B. Low level CD52 expression (ABC-1,317). C. Negative for CD52. X axis- CD3, Y-axis CD52, oval indicates malignant cells (based upon complete immunophenotypic data)
Figure 2
Figure 2
CD52 Expression in NK/T Cell Malignancies. CD52 expression as measured by anti-CD52-PE antibody. A. Positive for CD52 expression (ABC-1,336). B. Negative for CD52. X axis- CD56, Y-axis CD52, oval indicates malignant cells (based upon complete immunophenotypic data)
See this image and copyright information in PMC

References

    1. Alinari L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26:3644–3653. - PubMed
    1. Bindon CI, et al. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol. 1988;18:1507–1514. - PubMed
    1. Dearden CE, Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol. 2006;19:795–810. - PubMed
    1. Dearden CE, et al. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19(Suppl):S27–S32. - PubMed
    1. Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SMB, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJS, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726. - PubMed

MeSH terms